A change in drug pricing regimes has been predicted in the US after the 2008 presidential election, as both candidates have promised they will allow cheaper drugs to be imported, and encourage the growth of the generics market, by providing less protection to risk-taking innovators. This will profoundly reduce drug development in the future, and be of no public benefit in the longer term.